Suchergebnisse - "Sarilumab"

PubPharm (147)

51

Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters

enthalten in: Journal of clinical pharmacology | 2021

von Xu, C. | Rafique, A. | Potocky, T. | +12

52

A comprehensive review on sarilumab in COVID-19

enthalten in: Expert opinion on biological therapy | 2021

von Khiali, S. | Rezagholizadeh, A. | Entezari-Maleki, T.

53

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

enthalten in: The New England journal of medicine | 2021

von REMAP-CAP Investigators | Gordon, A. | Mouncey, P. | +160

CommentIn: N Engl J Med. 2021 Apr 22;384(16):1564-1565. - PMID 33631064

54

Platform Trials - Beware the Noncomparable Control Group

enthalten in: The New England journal of medicine | 2021

von Dodd, L. | Freidlin, B. | Korn, E.

55

Ludwig's angina in a rheumatoid arthritis patient taking sarilumab

enthalten in: Rheumatology (Oxford, England) | 2021

von Shiota, S. | Takakura, T. | Miyazaki, E.

56

COVID-19 and the burning issue of drug interaction : never forget the ECG

enthalten in: Postgraduate medical journal | 2021

von Sciaccaluga, C. | Cameli, M. | Menci, D. | +6

57

Treatment of COVID-19 : a review of current and prospective pharmacotherapies

enthalten in: British journal of hospital medicine (London, England : 2005) | 2021

von Quek, E. | Tahir, H. | Kumar, P. | +2

58

Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19

enthalten in: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research | 2021

von Khaedir, Y. | Kartika, R.

59

Biological agents for rheumatic diseases in the outbreak of COVID-19 : friend or foe?

enthalten in: RMD open | 2021

von Santos, C. | Férnandez, X. | Moriano Morales, C. | +4

60

Anti-IL6 treatment of serious COVID-19 disease : A monocentric retrospective experience

enthalten in: Medicine | 2021

von Castelnovo, L. | Tamburello, A. | Lurati, A. | +10